126 related articles for article (PubMed ID: 34678477)
61. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
[TBL] [Abstract][Full Text] [Related]
62. The Impact of Positive Peritoneal Cytology on the Survival Rates of Early-Stage-Disease Endometrial Cancer Patients: Systematic Review and Meta-Analysis.
Pergialiotis V; Panagiotopoulos M; Koutras A; Daras A; Ntounis T; Liontos M; Daskalakis G; Thomakos N
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792916
[No Abstract] [Full Text] [Related]
63. Outcomes Following Interval Debulking Surgery in Primary Peritoneal Carcinoma.
Connolly CF; Yahya S; Chan KK; Singh K; Sundar S; Anwar SM; Fernando I
Anticancer Res; 2016 Jan; 36(1):255-9. PubMed ID: 26722051
[TBL] [Abstract][Full Text] [Related]
64. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
Pepin K; Bregar A; Davis M; Melamed A; Hinchcliff E; Gockley A; Horowitz N; Del Carmen MG
Gynecol Oncol; 2017 Dec; 147(3):612-616. PubMed ID: 28988028
[TBL] [Abstract][Full Text] [Related]
65. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
[TBL] [Abstract][Full Text] [Related]
66. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract][Full Text] [Related]
67. The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer.
Bogani G; Leone Roberti Maggiore U; Paolini B; Diito A; Martinelli F; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2019 Jan; 30(1):e4. PubMed ID: 30479088
[TBL] [Abstract][Full Text] [Related]
68. What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?
Chiva L; Lapuente F; Castellanos T; Alonso S; Gonzalez-Martin A
Ann Surg Oncol; 2016 May; 23(5):1666-73. PubMed ID: 26714955
[TBL] [Abstract][Full Text] [Related]
69. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
Chern JY; Curtin JP
Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
[TBL] [Abstract][Full Text] [Related]
70. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
71. Role of peritoneal washing cytology in ovarian malignancies: correlation with histopathological parameters.
Naz S; Hashmi AA; Ali R; Faridi N; Hussian SD; Edhi MM; Khan M
World J Surg Oncol; 2015 Nov; 13():315. PubMed ID: 26556439
[TBL] [Abstract][Full Text] [Related]
72. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
[TBL] [Abstract][Full Text] [Related]
73. Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
Gueli Alletti S; Petrillo M; Vizzielli G; Bottoni C; Nardelli F; Costantini B; Quagliozzi L; Gallotta V; Scambia G; Fagotti A
Gynecol Oncol; 2016 Dec; 143(3):516-520. PubMed ID: 27769526
[TBL] [Abstract][Full Text] [Related]
74. Effects of pretreatment radiological and pathological lymph node statuses on prognosis in patients with ovarian cancer who underwent interval debulking surgery with lymphadenectomy following neoadjuvant chemotherapy.
Komatsu H; Iida Y; Osaku D; Shimogai R; Chikumi J; Sato S; Oishi T; Harada T
J Obstet Gynaecol Res; 2021 Jan; 47(1):152-158. PubMed ID: 32830400
[TBL] [Abstract][Full Text] [Related]
75. Interval debulking surgery for advanced epithelial ovarian cancer.
Tangjitgamol S; Manusirivithaya S; Laopaiboon M; Lumbiganon P
Cochrane Database Syst Rev; 2008 Oct; (4):CD006014. PubMed ID: 18843699
[TBL] [Abstract][Full Text] [Related]
76. Prognostic Value of Pathologic Chemotherapy Response Score in Patients With Ovarian Cancer After Neoadjuvant Chemotherapy.
Michaan N; Chong WY; Han NY; Lim MC; Park SY
Int J Gynecol Cancer; 2018 Nov; 28(9):1676-1682. PubMed ID: 30256239
[TBL] [Abstract][Full Text] [Related]
77. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.
Li S; Manning-Geist B; Gockley A; Ramos A; Sisodia RC; Del Carmen M; Growdon WB; Horowitz N; Berkowitz R; Worley M
Int J Gynecol Cancer; 2020 Jul; 30(7):1052-1057. PubMed ID: 32487686
[TBL] [Abstract][Full Text] [Related]
78. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
79. Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients.
Zuna RE; Behrens A
J Natl Cancer Inst; 1996 Jul; 88(14):980-7. PubMed ID: 8667429
[TBL] [Abstract][Full Text] [Related]
80. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
